share_log

Canaccord Genuity Maintains Buy on Rhythm Pharmaceuticals, Lowers Price Target to $79

Canaccord Genuity Maintains Buy on Rhythm Pharmaceuticals, Lowers Price Target to $79

Canaccord Genuity維持對Rhythm Pharmicals的買入,將目標股價下調
Benzinga ·  05/08 12:55

Canaccord Genuity analyst Whitney Ijem maintains Rhythm Pharmaceuticals (NASDAQ:RYTM) with a Buy and lowers the price target from $80 to $79.

Canaccord Genuity的分析師Whitney Ijem維持買入評級,將Rhythm Pharmaceuticals(納斯達克:RYTM)的目標價從80美元降至79美元。

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論